Brief and constraints
Pilot 30,000 units, ramp to 120,000 per year over 14 months. Vegan, paraben-free, sulphate-free, with a third-party clinical claim of 'visibly reduced frizz in 14 days'.
Budget envelope ₹85 – ₹110 landed. Founder wanted a defensible premium positioning that would survive a Nykaa or Tira shelf review.
The clinical claim was non-negotiable for shelf positioning — it is the single most cited filter in curly-hair consumer research.
The three formulation tiers we modelled
We always quote three tiers, never one flat price. It gives the founder real optionality and exposes where the spend actually shifts performance.
- ›GOOD (₹88): coco-glucoside surfactant base, fragrance from a Tier-2 house, stock 250ml HDPE, screen-printed label
- ›BETTER (₹96): blended mild surfactant + amino-acid co-actives, IFF fragrance, embossed cap, paper label with soy ink
- ›BEST (₹104): premium glucoside + amino-acid + bioactive moisturiser stack, perfumer-grade fragrance, soft-touch bottle finish, recycled HDPE
The clinical-test trap
Brands routinely quote the landed cost without baking in clinical-test cost. A 28-day study with 30 panelists in a CDSCO-notified clinical site runs ₹2.4 – ₹4.1 lakh, depending on photography, instrumental measurement (corneometry, sebumeter) and panel sourcing.
At 30,000 units, that is ₹8 – ₹14 per bottle if you amortise inside the first run. We recommend treating it as brand OPEX amortised over 2 years, not COGS — otherwise pilot pricing looks artificially weak.
Half the founders we see skip the clinical study and try to back-fit it post-launch. Without it, premium retail listing is materially harder and the claim itself is regulatorily fragile.
Where retail vs D2C economics diverge
At a ₹449 MRP, modern trade demands 42% margin (₹260 to the brand), bake in 8% trade promotions and you net ₹240 per bottle. Against ₹96 landed, contribution is ₹144 — healthy.
D2C-direct nets ₹449 minus 18% GST minus 4 – 6% payment-gateway/return cost = ₹354 per bottle. Contribution ₹258 against ₹96 — much stronger, but CAC eats it.
Most clean-beauty brands try to do both. The right answer in year one is D2C-only until repeat purchase data justifies a retail launch — typically month 9 or later.
Re-order economics
Pilot 30k locked at ₹96 landed. Re-order at 60k drops landed to ₹89 (negotiated raw-material strip + better fill efficiency). Re-order at 120k drops to ₹84.
The trap: at 120k, partners offer one-stop convenience that masks a 2 – 4% real margin compression for the brand if the founder doesn't re-quote alternates. Always re-quote at re-order — even if you stay with the same partner.
§ KEY TAKEAWAYS
- 01Always quote three formulation tiers, not one flat price
- 02Sulphate-free does not mean expensive — coco-glucoside is now commodity
- 03Clinical test cost belongs in brand OPEX, not COGS
- 04D2C-only in year one, retail launch month 9+ on real repeat data
- 05Always re-quote at re-order, even to the same partner
- 06Bake panel-photography cost into clinical-test budgeting upfront
§ GLOSSARY
Technical jargon, acronyms and scientific terms used in this file — decoded.
- HDPE
- High-Density Polyethylene — a rigid recyclable plastic widely used for shampoo and detergent bottles. Recyclable as resin code #2.
- Coco-glucoside
- A mild, plant-derived non-ionic surfactant used as a sulphate-free cleansing base.
- COGS
- Cost of Goods Sold — all direct costs of producing a unit (raw materials, packaging, fill, labelling, freight inbound).
- CDSCO
- Central Drugs Standard Control Organisation — India's apex regulator for cosmetics, drugs and medical devices.
- Corneometry
- Instrumental measurement of skin or hair hydration using an electrical capacitance probe — used to substantiate moisturisation claims.
- OPEX
- Operating Expenditure — recurring brand-side costs (marketing, salaries, clinical testing) treated as period expenses rather than per-unit COGS.
